Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium vs Paroxetine in Depression with Bipolar Family History
NCT00400088Phase 3Terminated
- Sponsor
- Nova Scotia Health
- Start
- Jun 2007
- Primary completion
- Jan 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lithium in major depressive disorder (MDD) (2 arms), sponsored by Nova Scotia Health. Primary endpoints: Response (50% reduction in MADRS score), Remission (MADRS <= 12) and 1 more. Started Jun 2007; status: terminated.
02
Drugs
lithium
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00400088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400088.